Application of Cancer Organoid Model for Drug Screening and Personalized Therapy

Area of Science:

• Oncology
• Drug Discovery
• Translational Medicine

Background:

• Intertumoral heterogeneity presents a significant challenge in developing standardized cancer treatments.
• Conventional 2D cell lines lack the physiological relevance needed for effective drug screening.
• Improved cancer models are crucial for evaluating drug efficacy and understanding disease complexity.

Purpose of the Study:

• To review recent advancements in experimental cancer models for drug screening.
• To highlight the potential of cancer organoids as superior disease models.
• To discuss the application of cancer organoids in studying heterogeneity and enabling precision medicine.

Main Methods:

• Review of current literature on experimental cancer models.
• Focus on cancer organoid technology for drug screening.
• Analysis of organoid utility in assessing intertumor and intratumor heterogeneity.

Main Results:

• Cancer organoids demonstrate greater physiological and clinical relevance than 2D cell lines for drug screening.
• Organoids effectively model both intertumor and intratumor heterogeneity.
• Emerging evidence supports the clinical application of organoids for personalized cancer therapy.

Conclusions:

• Cancer organoids represent a promising advancement over traditional models for drug discovery and development.
• Organoid technology facilitates a deeper understanding of cancer heterogeneity.
• The clinical implementation of cancer organoids is key to achieving precision medicine in oncology.